Similar Search Results

Public acceptance of different approaches to determine drug reimbursement prices and whether it is influenced by framing : An empirical evaluation in Germany

Gandjour, Afschin; Chernyak, Nadja; Icks, Andrea; … - In: International Journal of Public Sector Management 27 (2014) 6, pp. 501-511

Purpose – In Germany, the Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)) makes recommendations for reimbursement prices of drugs based on an evaluation of the relationship between incremental costs and effects....

Persistent link: https://www.econbiz.de/10014799781

Effizienzbewertung im Rahmen des GKV-Versorgungsstärkungsgesetzes : was kann die Gesundheitsökonomie hierzu beitragen?

Dintsios, Charalabos-Markos; Icks, Andrea; … - In: Sozialer Fortschritt : unabhängige Zeitschrift für … 66 (2017) 10, pp. 651-673

Persistent link: https://www.econbiz.de/10011862046

Presenting Germany's drug pricing rule as a cost-per-QALY rule

Gandjour, Afschin - In: Health care management science 15 (2012) 2, pp. 103-107

Persistent link: https://www.econbiz.de/10009551689

Commentary to: cost of poor adherence to anti-hypertensive therapy in five European countries

Gandjour, Afschin - In: The European journal of health economics : HEPAC ; … 16 (2015) 8, pp. 907

Persistent link: https://www.econbiz.de/10011483857

Comment on "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany"

Gandjour, Afschin - In: The European journal of health economics : HEPAC ; … 19 (2018) 3, pp. 471-472

Persistent link: https://www.econbiz.de/10011952176

The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany

Gandjour, Afschin - In: The quarterly review of economics and finance : journal … 84 (2022), pp. 502-509

Persistent link: https://www.econbiz.de/10013335893

Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany : a comment

Gandjour, Afschin - In: The European journal of health economics 24 (2023) 7, pp. 1243-1244

Persistent link: https://www.econbiz.de/10014328184

Reply to comment on cost of poor adherence to anti-hypertensive therapy in five European countries

Mennini, F. S.; Marcellusi, Andrea; Schulenburg, … - In: The European journal of health economics : HEPAC ; … 16 (2015) 8, pp. 909-911

Persistent link: https://www.econbiz.de/10011483858

Gesundheitswirtschaftliche Gesamtrechnung 2000-2014 : Gutachten für das Bundesministerium für Wirtschaft und Energie

Schneider, Markus; Krauss, Thomas; Hofmann, Uwe; Köse, … - Deutschland / Bundesministerium für Wirtschaft und Energie - 2016 - 1. Auflage

Persistent link: https://www.econbiz.de/10011436556

Authors' reply to Gandjour: "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany"

Kuhlmann, Alexander; Schulenburg, Johann-Matthias von der - In: The European journal of health economics : HEPAC ; … 19 (2018) 3, pp. 473-481

Persistent link: https://www.econbiz.de/10011952179